A number of research firms have changed their ratings and price targets for Lumos Pharma (NASDAQ: LUMO): 8/22/2023 – Lumos Pharma had its “overweight” rating reaffirmed by analysts at Cantor Fitzgerald. They now have a $10.00 price target on the stock. 8/15/2023 – Lumos Pharma had its price target lowered by analysts at Cantor Fitzgerald […]
Cantor Fitzgerald reiterated their overweight rating on shares of Lumos Pharma (NASDAQ:LUMO – Free Report) in a research report sent to investors on Tuesday morning, Benzinga reports. They currently have a $10.00 price target on the stock. Several other research firms also recently issued reports on LUMO. Oppenheimer cut their price objective on Lumos Pharma […]
HC Wainwright reiterated their buy rating on shares of Lumos Pharma (NASDAQ:LUMO – Free Report) in a report published on Thursday morning, Benzinga reports. The brokerage currently has a $28.00 target price on the stock. Separately, Cantor Fitzgerald reaffirmed an overweight rating and set a $14.00 price target on shares of Lumos Pharma in a […]
Lumos Pharma (NASDAQ:LUMO – Free Report) had its target price cut by Oppenheimer from $18.00 to $17.00 in a research report sent to investors on Thursday, Benzinga reports. They currently have an outperform rating on the stock. LUMO has been the subject of a number of other research reports. HC Wainwright reiterated a buy rating […]
Lumos Pharma (NASDAQ:LUMO – Get Free Report) will be releasing its earnings data after the market closes on Wednesday, August 9th. Analysts expect Lumos Pharma to post earnings of ($1.06) per share for the quarter. Individual that wish to register for the company’s earnings conference call can do so using this link. Lumos Pharma Stock […]